Hanall Biopharma Signs Exclusive Distribution Agreement for Korean Sandoz's Hyperlipidemia Treatment 'Stavaster Tablets'
[Asia Economy Reporter Lee Gwan-joo] HanAll Biopharma announced on the 15th that it has signed an exclusive domestic sales contract for the hyperlipidemia treatment drug ‘Starvaster Tab’ with Korea Sandoz, a subsidiary of Novartis specializing in generics and biosimilars.
Under this agreement, HanAll Biopharma will be granted exclusive sales rights for ‘Starvaster Tab’ (active ingredient rosuvastatin) in addition to the already marketed ‘Sandoz Atorvastatin Tab’ (active ingredient atorvastatin). Korea Sandoz will be responsible for supplying Starvaster Tab, while HanAll will handle domestic distribution and promotional activities. The domestic market size for rosuvastatin has shown an average annual growth rate of 6.2% over the past three years, reaching 331.6 billion KRW last year.
Starvaster Tab is a generic product containing the active ingredient rosuvastatin, widely prescribed for the treatment of hypercholesterolemia and prevention of cardiovascular diseases. With the addition of Starvaster Tab, HanAll has expanded its portfolio of hyperlipidemia treatments, including the existing combination drug ‘Hantojet’ (active ingredients atorvastatin and ezetimibe).
Park Seung-guk, CEO of HanAll Biopharma, said, “HanAll Biopharma has collaborated with Korea Sandoz for over 10 years to introduce high-quality pharmaceuticals,” adding, “Starting with this contract, we will strengthen our partnership with Sandoz to provide patients with a wider range of treatment options.”
Hot Picks Today
Up to 600 Million Won for Semiconductors, 160 Million Won Bonus for Loss-Making Non-Memory… Samsung Electronics Labor and Management Reach Tentative Deal on Unprecedented Performance Compensation (Comprehensive)
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- [Exclusive] 450 Billion Won Korean Investment at Risk as Canadian PE Moves to Acquire US Ascend for $99.2 Million
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Ahn Hee-kyung, CEO of Korea Sandoz, stated, “Sandoz Atorvastatin Tab and Starvaster Tab are high-quality pharmaceuticals that have passed cGMP standards and are recognized by clinics,” and added, “Based on HanAll’s solid sales capabilities, we will expand the sales base of hyperlipidemia treatments and other products currently under development and sales, further strengthening our position in the domestic market.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
